Related Experiment Video

Updated: May 22, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

Non-steroidal anti-inflammatory drugs and melanoma

Virginia Sanz-Motilva1, Antonio Martorell-Calatayud, Eduardo Nagore

  • 1Dermatology Department, Hospital Universitario 12 de Octubre, Avenida de Córdoba s/n. 28026, Madrid, Spain. vsanzmotilva@hotmail.com

Current Pharmaceutical Design
|May 29, 2012
PubMed

Insights

Inflammation fuels cancer growth, particularly in skin cancer like melanoma. COX inhibitors, such as NSAIDs, show anti-tumor effects by blocking inflammatory prostaglandins and altering gene expression.

Area of Science:

  • Oncology
  • Dermatology
  • Inflammation Research

Background:

  • Inflammation is a key factor in the development and progression of human cancers.
  • Prostaglandins, formed by cyclooxygenases (COXs), are inflammatory lipid metabolites that promote tumor growth.
  • Non-steroidal anti-inflammatory drugs (NSAIDs) are known to inhibit tumor growth and development.

Purpose of the Study:

  • To review the role of inflammation in cutaneous malignant melanoma pathogenesis.
  • To explore the impact of inflammation on melanoma progression.
  • To identify potential new therapeutic targets for melanoma.

Main Methods:

  • Literature review on inflammation in cancer.
  • Focus on prostaglandin synthesis and cyclooxygenase (COX) inhibition.
  • Examination of NSAID mechanisms beyond COX inhibition.

Main Results:

  • Inflammatory lipid metabolites (prostaglandins) activate signaling pathways driving tumor progression.
  • NSAIDs inhibit tumor growth and development, partly through COX inhibition.
  • NSAIDs also exhibit anti-tumorigenic activity via COX-independent gene expression alterations.

Conclusions:

  • Inflammation plays a significant role in the pathogenesis of cutaneous malignant melanoma.
  • Understanding inflammation's impact may lead to novel therapeutic strategies for melanoma.
  • Further research into inflammation and melanoma could yield new treatment targets.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...